JP2014501784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014501784A5 JP2014501784A5 JP2013548578A JP2013548578A JP2014501784A5 JP 2014501784 A5 JP2014501784 A5 JP 2014501784A5 JP 2013548578 A JP2013548578 A JP 2013548578A JP 2013548578 A JP2013548578 A JP 2013548578A JP 2014501784 A5 JP2014501784 A5 JP 2014501784A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- iron
- pharmaceutical composition
- oral dosage
- iron compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006186 oral dosage form Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 150000002506 iron compounds Chemical class 0.000 claims 12
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 10
- 229920000642 polymer Polymers 0.000 claims 9
- 238000010521 absorption reaction Methods 0.000 claims 8
- 239000003623 enhancer Substances 0.000 claims 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 6
- -1 medium chain fatty acid salt Chemical class 0.000 claims 6
- 239000003826 tablet Substances 0.000 claims 6
- 239000000654 additive Substances 0.000 claims 5
- 230000000996 additive effect Effects 0.000 claims 5
- 230000003111 delayed effect Effects 0.000 claims 5
- 229910052742 iron Inorganic materials 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- 230000010437 erythropoiesis Effects 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 239000008188 pellet Substances 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims 2
- 206010022971 Iron Deficiencies Diseases 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Chemical class 0.000 claims 2
- 229960005070 ascorbic acid Drugs 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 150000002505 iron Chemical class 0.000 claims 2
- 239000008185 minitablet Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N Folic acid Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 229940124532 absorption promoter Drugs 0.000 claims 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims 1
- 229960004050 aminobenzoic acid Drugs 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 235000001465 calcium Nutrition 0.000 claims 1
- 239000013522 chelant Substances 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229910052804 chromium Inorganic materials 0.000 claims 1
- 239000011651 chromium Substances 0.000 claims 1
- 235000012721 chromium Nutrition 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 229910052802 copper Inorganic materials 0.000 claims 1
- 239000010949 copper Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002702 enteric coating Substances 0.000 claims 1
- 238000009505 enteric coating Methods 0.000 claims 1
- 235000007144 ferric diphosphate Nutrition 0.000 claims 1
- 239000011706 ferric diphosphate Substances 0.000 claims 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims 1
- 229940036404 ferric pyrophosphate Drugs 0.000 claims 1
- 235000003891 ferrous sulphate Nutrition 0.000 claims 1
- 239000011790 ferrous sulphate Substances 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 125000003929 folic acid group Chemical group 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- SXAWSYZURCZSDX-UHFFFAOYSA-B hydron;[hydroxy(oxido)phosphoryl] hydrogen phosphate;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+);phosphonato phosphate Chemical compound [H+].[H+].[H+].[H+].[H+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OP([O-])(=O)OP(O)([O-])=O.OP([O-])(=O)OP(O)([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O SXAWSYZURCZSDX-UHFFFAOYSA-B 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 1
- 229960000367 inositol Drugs 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 150000004698 iron complex Chemical class 0.000 claims 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims 1
- 239000013563 matrix tablet Substances 0.000 claims 1
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000002861 polymer material Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 1
- 239000011669 selenium Substances 0.000 claims 1
- 229910052711 selenium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229960005480 sodium caprylate Drugs 0.000 claims 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 claims 1
- 229940082004 sodium laurate Drugs 0.000 claims 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical group [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- FIWQZURFGYXCEO-UHFFFAOYSA-M sodium;decanoate Chemical compound [Na+].CCCCCCCCCC([O-])=O FIWQZURFGYXCEO-UHFFFAOYSA-M 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 235000019155 vitamin A Nutrition 0.000 claims 1
- 239000011719 vitamin A Substances 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 229940045997 vitamin a Drugs 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161430575P | 2011-01-07 | 2011-01-07 | |
| US61/430,575 | 2011-01-07 | ||
| PCT/US2012/020487 WO2012094598A2 (en) | 2011-01-07 | 2012-01-06 | Pharmaceutical compositions of iron for oral administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014501784A JP2014501784A (ja) | 2014-01-23 |
| JP2014501784A5 true JP2014501784A5 (enExample) | 2015-02-26 |
Family
ID=46457982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013548578A Pending JP2014501784A (ja) | 2011-01-07 | 2012-01-06 | 経口投与用の鉄の医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8802114B2 (enExample) |
| EP (1) | EP2661273A4 (enExample) |
| JP (1) | JP2014501784A (enExample) |
| KR (1) | KR20140026354A (enExample) |
| CN (1) | CN103476419A (enExample) |
| AU (1) | AU2012204213A1 (enExample) |
| BR (1) | BR112013017169A2 (enExample) |
| CA (1) | CA2819234A1 (enExample) |
| WO (1) | WO2012094598A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US20090280169A1 (en) * | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
| TWI480286B (zh) * | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | 雙膦酸鹽類組合物及藥物遞送 |
| US20110182985A1 (en) * | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| WO2011120033A1 (en) * | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| EP2579868B1 (en) * | 2010-06-09 | 2018-03-07 | Emisphere Technologies, Inc. | Oral iron deficiency therapy |
| CA2900043A1 (en) * | 2013-02-01 | 2014-08-07 | Charak Llc | Methods of treating iron deficiency with soluble ferric pyrophosphate |
| PL3048903T3 (pl) * | 2013-08-28 | 2017-09-29 | Dsm Ip Assets B.V. | Suplementacja żelaza koncentratu bulionu |
| ES2683212T3 (es) * | 2013-08-28 | 2018-09-25 | Dsm Ip Assets B.V. | Complementación de hierro de un concentrado de caldo |
| US20160250254A1 (en) * | 2013-11-05 | 2016-09-01 | Rockwell Medical, Inc. | Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients |
| US9492421B1 (en) * | 2013-11-14 | 2016-11-15 | Argent Development Group, Llc | Nutritional supplements for treatment of iron deficiency anemia |
| JP7211704B2 (ja) | 2015-01-29 | 2023-01-24 | ノヴォ ノルディスク アー／エス | Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤 |
| GB201515387D0 (en) * | 2015-08-28 | 2015-10-14 | Amazentis Sa | Compositions |
| CN106344534B (zh) * | 2016-09-30 | 2019-07-19 | 广西科技大学 | 硫酸亚铁肠溶滴丸的制备方法 |
| US10940116B2 (en) * | 2017-10-25 | 2021-03-09 | Chiesi Farmaceutici S.P.A. | Delayed release deferiprone tablets and methods of using the same |
| KR102084489B1 (ko) * | 2018-05-18 | 2020-03-04 | 강원대학교산학협력단 | 열용융압출법을 이용하여 제조된 철 나노콜로이드 분산체 및 이의 용도 |
| CN112955158A (zh) * | 2018-09-05 | 2021-06-11 | 康肾医药有限公司 | 含铁组合物及其用途 |
| TWI717139B (zh) * | 2018-12-20 | 2021-01-21 | 普惠德生技股份有限公司 | 含有亞鐵胺基酸螯合物粒子的組合物用於製備治療或減緩自體免疫相關疾病的醫藥品的用途 |
| WO2020230090A1 (en) * | 2019-05-14 | 2020-11-19 | Nokha Trading Llp | Ferrous sulphate oral compositions |
| CN111714470B (zh) * | 2020-05-27 | 2022-04-08 | 天津瑞益瑞美生物技术有限公司 | 一种兽用肠溶乙二胺四乙酸铁钠预混剂及其制备方法 |
| US12016851B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
| US12016850B2 (en) | 2022-04-11 | 2024-06-25 | Chiesi Farmaceutici S.P.A. | Modified release pharmaceutical formulations comprising deferiprone |
Family Cites Families (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB953626A (en) | 1961-04-25 | 1964-03-25 | Meito Sangyo Kk | Enteric-coated tablets of dextran sulphate ester and method of preparation thereof |
| US4525339A (en) | 1982-10-15 | 1985-06-25 | Hoffmann-La Roche Inc. | Enteric coated oral dosage form |
| WO1984004674A1 (en) | 1983-05-31 | 1984-12-06 | Jang Choong Gook | Dry direct compression compositions for controlled release dosage forms |
| DE3331009A1 (de) | 1983-08-27 | 1985-03-14 | Basf Ag, 6700 Ludwigshafen | Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat |
| US4590062A (en) | 1984-04-16 | 1986-05-20 | Tech Trade Corp. | Dry direct compression compositions for controlled release dosage forms |
| US4654155A (en) | 1985-03-29 | 1987-03-31 | Reynolds Metals Company | Microemulsion lubricant |
| US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
| US4764375A (en) | 1985-09-11 | 1988-08-16 | Kv Pharmaceutical Company | Sachet drug delivery system |
| US4789547A (en) | 1987-06-17 | 1988-12-06 | Warner-Lambert Company | Transdermal matrix system |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| US5221734A (en) | 1987-10-01 | 1993-06-22 | Ciba-Geigy Corporation | Process for preparing a polypeptide growth factor for milk |
| GB2212396A (en) * | 1987-12-18 | 1989-07-26 | Procter & Gamble | Dietary supplement comprising calcium and delayed release coated iron |
| NZ228285A (en) | 1988-03-11 | 1991-08-27 | Teikoku Seiyaku Kk | Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration |
| US5169933A (en) | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| ZA898331B (en) | 1988-11-22 | 1990-07-25 | Hoffmann La Roche | Pharmaceutical compositions |
| US5190748A (en) | 1988-11-22 | 1993-03-02 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
| IL92537A (en) | 1988-12-15 | 1994-04-12 | Riker Laboratories Inc | Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine |
| GB2244015B (en) | 1990-03-14 | 1993-10-27 | Hadley Sections Limited | Tube and method of forming same |
| US5541155A (en) | 1994-04-22 | 1996-07-30 | Emisphere Technologies, Inc. | Acids and acid salts and their use in delivery systems |
| US5110606A (en) | 1990-11-13 | 1992-05-05 | Affinity Biotech, Inc. | Non-aqueous microemulsions for drug delivery |
| IT1245761B (it) | 1991-01-30 | 1994-10-14 | Alfa Wassermann Spa | Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale. |
| US5744450A (en) | 1991-03-14 | 1998-04-28 | The Salk Institute For Biological Studies | GnRH analogs |
| DE69229779T2 (de) | 1991-04-19 | 1999-12-23 | Lds Technologies, Inc. | Konvertierbare mikroemulsionsverbindungen |
| US5688761A (en) | 1991-04-19 | 1997-11-18 | Lds Technologies, Inc. | Convertible microemulsion formulations |
| CA2070061C (en) | 1991-06-07 | 2004-02-10 | Shigeyuki Takama | Physiologically active polypeptide-containing pharmaceutical composition |
| CZ282760B6 (cs) | 1991-11-22 | 1997-09-17 | Procter And Gamble Pharmaceuticals, Inc. | Risedronátové prostředky se zpožděným uvolňováním |
| US5229130A (en) | 1991-12-20 | 1993-07-20 | Cygnus Therapeutics Systems | Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems |
| SE501389C2 (sv) | 1992-04-24 | 1995-01-30 | Leiras Oy | Farmaceutiskt preparat och förfarande för dess framställning |
| DE4317458A1 (de) | 1992-06-11 | 1993-12-16 | Bayer Ag | Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung |
| JP3190441B2 (ja) | 1992-07-20 | 2001-07-23 | エーザイ株式会社 | 塩酸アゼラスチンを含有する安定な製剤 |
| RU2068689C1 (ru) | 1992-09-24 | 1996-11-10 | Товарищество с ограниченной ответственностью "Лекрон" | Способ получения таблеток парацетамола |
| WO1994010983A1 (fr) | 1992-11-06 | 1994-05-26 | Hisamitsu Pharmaceutical Co., Inc. | Preparation pharmaceutique perorale liberable dans le tube digestif inferieur |
| US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
| SE9302135D0 (sv) | 1993-06-18 | 1993-06-18 | Kabi Pharmacia Ab | New pharmaceutical composition |
| TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
| ES2068762B1 (es) | 1993-07-21 | 1995-12-01 | Lipotec Sa | Un nuevo preparado farmaceutico para mejorar la biodisponibilidad de drogas de dificil absorcion y procedimiento para su obtencion. |
| AU692506B2 (en) | 1993-11-17 | 1998-06-11 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
| JP4040084B2 (ja) | 1994-02-16 | 2008-01-30 | アボツト・ラボラトリーズ | 微粒子医薬調合物の調製プロセス |
| US5506207A (en) | 1994-03-18 | 1996-04-09 | The Salk Institute For Biological Studies | GNRH antagonists XIII |
| IL110024A (en) | 1994-06-15 | 1998-04-05 | Yissum Res Dev Co | Controlled release oral drug delivery system containing hydrogel- forming polymer |
| US5639469A (en) | 1994-06-15 | 1997-06-17 | Minnesota Mining And Manufacturing Company | Transmucosal delivery system |
| GB9414318D0 (en) | 1994-07-15 | 1994-09-07 | Dowelanco Ltd | Preparation of aqueous emulsions |
| ATE220911T1 (de) | 1994-11-17 | 2002-08-15 | Toray Industries | Transdermal absorbierbare zubereitung |
| US6524557B1 (en) | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| JPH11505258A (ja) | 1995-05-17 | 1999-05-18 | セダーシナイ メディカル センター | 小腸における消化および吸収を改善させる脂肪酸を含む組成物 |
| US6572879B1 (en) | 1995-06-07 | 2003-06-03 | Alza Corporation | Formulations for transdermal delivery of pergolide |
| US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
| GB9516268D0 (en) | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
| US5626884A (en) * | 1995-08-18 | 1997-05-06 | Lockett; Curtis G. | Treatment of sickle cell disease |
| US5766620A (en) | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
| US5807983A (en) | 1995-12-28 | 1998-09-15 | The Salk Institute For Biological Studies | GNRH antagonist betides |
| JP2000511532A (ja) | 1996-05-20 | 2000-09-05 | メルク エンド カンパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモンのアンタゴニスト |
| US6147088A (en) | 1996-05-20 | 2000-11-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6150522A (en) | 1996-05-20 | 2000-11-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
| US5916582A (en) | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
| GB9614235D0 (en) | 1996-07-06 | 1996-09-04 | Danbiosyst Uk | Composition for enhanced uptake of polar drugs from mucosal surfaces |
| AU717183B2 (en) | 1996-10-30 | 2000-03-16 | Theratech, Inc. | Fatty acid esters of lactic acid salts as permeation enhancers |
| US5821230A (en) | 1997-04-11 | 1998-10-13 | Ferring Bv | GnRH antagonist decapeptides |
| US5925730A (en) | 1997-04-11 | 1999-07-20 | Ferring Bv | GnRH antagonists |
| US5981550A (en) | 1997-06-05 | 1999-11-09 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6004984A (en) | 1997-06-05 | 1999-12-21 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6156767A (en) | 1997-06-05 | 2000-12-05 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6156772A (en) | 1997-06-05 | 2000-12-05 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| ATE321882T1 (de) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| IL121269A0 (en) | 1997-07-09 | 1998-01-04 | Dpharm Ltd | Compositions and methods for reversibly increasing permeability of biomembranes |
| IL121268A0 (en) | 1997-07-09 | 1998-01-04 | Dpharm Ltd | Branched chain fatty acids their derivatives and use in the treatment of central nervous system disorders |
| SE9703691D0 (sv) | 1997-10-10 | 1997-10-10 | Astra Ab | Pharmaceutical compositions |
| US6017944A (en) | 1997-10-28 | 2000-01-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| KR20010041696A (ko) | 1998-03-11 | 2001-05-25 | 그레랑 파마수티컬 가부시키가이샤 | 발포성 장용(腸溶) 제제 |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US5998432A (en) | 1998-04-02 | 1999-12-07 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6077847A (en) | 1998-04-02 | 2000-06-20 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6270804B1 (en) | 1998-04-03 | 2001-08-07 | Biovail Technologies Ltd. | Sachet formulations |
| GB2336311A (en) | 1998-04-15 | 1999-10-20 | Merck & Co Inc | Bisphosphonate Dosing Regimen |
| US6656922B2 (en) | 1998-05-28 | 2003-12-02 | Mediplex Corporation, Korea | Oral delivery of macromolecules |
| JP3853985B2 (ja) * | 1998-08-03 | 2006-12-06 | 有限会社 健康百二十才 | 鉄イオン含有殺菌液 |
| AU1071200A (en) | 1998-10-19 | 2000-05-08 | Biotech Australia Pty Limited | Systems for oral delivery |
| US20070148228A1 (en) | 1999-02-22 | 2007-06-28 | Merrion Research I Limited | Solid oral dosage form containing an enhancer |
| US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
| US8119159B2 (en) | 1999-02-22 | 2012-02-21 | Merrion Research Iii Limited | Solid oral dosage form containing an enhancer |
| DE60038097T2 (de) * | 1999-02-22 | 2009-02-12 | Merrion Research I Ltd. | Feste orale dosierungsform enthaltend einen resorptionsverstärker |
| SE9901272D0 (sv) | 1999-04-09 | 1999-04-09 | Astra Ab | New improved formulation |
| JP2001081031A (ja) | 1999-08-30 | 2001-03-27 | Schering Ag | 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤 |
| ES2347284T3 (es) | 1999-12-08 | 2010-10-27 | Cyclacel Pharmaceuticals, Inc. | Uso de depsipeptido y congeneres del mismo como inmunosupresores en la prevencion o tratamiento del rechazo que sigue a un transplante y para inducir la apoptosis de celulas t cd4 o cd8 activadas. |
| US20010044427A1 (en) | 1999-12-20 | 2001-11-22 | Sidney Mazel | Pharmaceutical kit |
| US20020002140A1 (en) | 2000-01-14 | 2002-01-03 | Holick Michael F. | Novel bisphosphonates and uses thereof |
| CA2405360A1 (en) | 2000-04-07 | 2001-10-18 | The Board Of Regents Of The University Of Texas System | Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity |
| US6468559B1 (en) | 2000-04-28 | 2002-10-22 | Lipocine, Inc. | Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods |
| IT1318539B1 (it) | 2000-05-26 | 2003-08-27 | Italfarmaco Spa | Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente |
| CN1141974C (zh) | 2000-06-07 | 2004-03-17 | 张昊 | 结肠定位释放的口服生物制剂 |
| SK287278B6 (sk) | 2000-06-20 | 2010-05-07 | Novartis Ag | Použitie kyseliny 1-hydroxy-2-(imidazol-1-yl)etán-1,1- difosfónovej na prípravu liečiva na liečenie stavov abnormálne zvýšeného kostného obratu |
| WO2002055017A2 (en) | 2000-11-21 | 2002-07-18 | Wake Forest University | Method of treating autoimmune diseases |
| GB0029111D0 (en) | 2000-11-29 | 2001-01-10 | Novartis Ag | Organic compounds |
| US6379960B1 (en) | 2000-12-06 | 2002-04-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of damage-specific DNA binding protein 2, p48 expression |
| US20020103131A1 (en) | 2001-01-26 | 2002-08-01 | Jacobson Jill D. | Prevention of diabetes by administration of GnRH antagonists |
| KR20040018333A (ko) | 2001-02-16 | 2004-03-03 | 시미즈 세이야꾸 가부시키가이샤 | 소장 전달용 점액다당류 함유 경구 제형, 및 순환 장애치료에서의 이들의 용도 |
| WO2002070438A2 (en) | 2001-03-01 | 2002-09-12 | Emisphere Technologies, Inc. | Compositions for delivering bisphosphonates |
| RU2297229C2 (ru) | 2001-05-02 | 2007-04-20 | Новартис Аг | Фармацевтическое применение бисфосфонатов |
| CA2446622C (en) | 2001-05-11 | 2012-08-14 | Elan Corporation, Plc | Isostearic acid salts as permeation enhancers |
| JP4381805B2 (ja) | 2001-07-02 | 2009-12-09 | メリオン リサーチ スリー リミテッド | 生物活性材料の送達 |
| US20030031757A1 (en) * | 2001-08-03 | 2003-02-13 | Kraft Food Holdings, Inc. | Stable and bioavailable iron fortified beverages |
| US6716814B2 (en) * | 2001-08-16 | 2004-04-06 | Albion International, Inc. | Enhancing solubility of iron amino acid chelates and iron proteinates |
| US7098305B2 (en) | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| DE10157628A1 (de) | 2001-11-26 | 2003-06-12 | Zentaris Ag | Injektionslösung eines LHRH-Antagonisten |
| US7214662B2 (en) | 2001-11-27 | 2007-05-08 | Zentaris Gmbh | Injectable solution of an LHRH antagonist |
| US8535650B2 (en) | 2001-12-03 | 2013-09-17 | Soligenix, Inc. | Stabilized reverse micelle compositions and uses thereof |
| JP2005516928A (ja) | 2001-12-13 | 2005-06-09 | メルク エンド カムパニー インコーポレーテッド | 骨異常のためのビスホスホネート液体製剤 |
| NZ533060A (en) | 2001-12-19 | 2006-03-31 | Alza Corp | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| CN1330370C (zh) | 2002-02-28 | 2007-08-08 | 尼普洛株式会社 | 稳定的白蛋白制剂 |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| CA2763775C (en) | 2002-05-10 | 2014-01-07 | F. Hoffmann-La Roche Ag | Bisphosphonic acids for the treatment and prevention of osteoporosis |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2005020913A2 (en) | 2003-08-25 | 2005-03-10 | Combinatorx, Incorporated | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms |
| MXPA06003063A (es) | 2003-09-19 | 2006-05-31 | Pfizer Prod Inc | Composiciones farmaceuticas y metodos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina- d y un bisfosfonato. |
| WO2005041926A1 (en) * | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid |
| US8987322B2 (en) | 2003-11-04 | 2015-03-24 | Circ Pharma Research And Development Limited | Pharmaceutical formulations for carrier-mediated transport statins and uses thereof |
| DE10358525A1 (de) | 2003-12-13 | 2005-07-07 | Bayer Healthcare Ag | Endoparasitizide Mittel zur topischen Applikation |
| AR046773A1 (es) | 2003-12-23 | 2005-12-21 | Novartis Ag | Formulaciones farmaceuticas de bisfosfonatos |
| WO2005062041A1 (en) | 2003-12-24 | 2005-07-07 | Astrazeneca Ab | Pharmaceutical dissolution testing using a non-ionic surfactant |
| US7606313B2 (en) | 2004-01-15 | 2009-10-20 | Ittiam Systems (P) Ltd. | System, method, and apparatus for error concealment in coded video signals |
| WO2005072747A1 (ja) | 2004-02-02 | 2005-08-11 | Ono Pharmaceutical Co., Ltd. | 骨吸収抑制剤 |
| US20050232981A1 (en) | 2004-04-15 | 2005-10-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| US20070219131A1 (en) | 2004-04-15 | 2007-09-20 | Ben-Sasson Shmuel A | Compositions capable of facilitating penetration across a biological barrier |
| US20070212395A1 (en) | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| EP2269584B1 (en) | 2004-05-24 | 2022-04-13 | Allergan Pharmaceuticals International Limited | Enteric solid oral dosage form of a bisphosphonate containing a chelating agent |
| CA2574085C (en) | 2004-07-16 | 2014-02-11 | Oakwood Laboratories, L.L.C. | Gonadotropin releasing hormone antagonists |
| WO2006014673A2 (en) | 2004-07-19 | 2006-02-09 | Nobex Corporation | Insulin-oligomer conjugates, formulations and uses thereof |
| US8710181B2 (en) | 2004-08-31 | 2014-04-29 | Novo Nordisk A/S | Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins |
| EP1674082A1 (de) | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| EP1865928A1 (en) | 2005-03-17 | 2007-12-19 | Elan Pharma International Limited | Nanoparticulate biphosphonate compositions |
| TWI372629B (en) | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| IL174387A0 (en) | 2005-03-31 | 2008-01-20 | Dexcel Pharma Technologies Ltd | A solid composition for intra-oral delivery of insulin |
| EP2974718A1 (en) * | 2005-04-29 | 2016-01-20 | Cubist Pharmaceuticals, Inc. | Therapeutic compositions |
| EP1888117A1 (en) | 2005-05-25 | 2008-02-20 | Novo Nordisk A/S | Stabilized polypeptide formulations |
| CA2612508A1 (en) | 2005-06-17 | 2006-12-28 | Dynamis Therapeutics, Inc. | Treatment of inflammatory conditions |
| ZA200801696B (en) | 2005-07-22 | 2009-08-26 | Univ California | Heparin compositions and selection inhibition |
| US20070077313A1 (en) | 2005-10-04 | 2007-04-05 | U.S. Pharmaceutical Corporation | Toleration iron supplement compositions |
| BRPI0710503A2 (pt) | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
| EP2040731A4 (en) | 2006-06-09 | 2010-05-19 | Merrion Res Iii Ltd | SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR |
| US20090004281A1 (en) | 2007-06-26 | 2009-01-01 | Biovail Laboratories International S.R.L. | Multiparticulate osmotic delivery system |
| CN101125132A (zh) | 2007-07-25 | 2008-02-20 | 司炳奎 | 口服胰岛素肠溶胶囊及其制备方法 |
| US20090280169A1 (en) | 2008-05-07 | 2009-11-12 | Merrion Research Iii Limited | Compositions of peptides and processes of preparation thereof |
| HRP20170929T1 (hr) | 2008-09-17 | 2017-09-22 | Chiasma Inc. | Farmaceutski pripravci i odgovarajući postupci za isporuku |
| TWI480286B (zh) | 2009-02-25 | 2015-04-11 | Merrion Res Iii Ltd | 雙膦酸鹽類組合物及藥物遞送 |
| US20110182985A1 (en) | 2010-01-28 | 2011-07-28 | Coughlan David C | Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof |
| WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
| CA2819108A1 (en) | 2010-12-15 | 2012-06-21 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
-
2012
- 2012-01-06 AU AU2012204213A patent/AU2012204213A1/en not_active Abandoned
- 2012-01-06 CN CN2012800046818A patent/CN103476419A/zh active Pending
- 2012-01-06 US US13/345,185 patent/US8802114B2/en not_active Expired - Fee Related
- 2012-01-06 KR KR1020137017418A patent/KR20140026354A/ko not_active Withdrawn
- 2012-01-06 CA CA2819234A patent/CA2819234A1/en not_active Abandoned
- 2012-01-06 WO PCT/US2012/020487 patent/WO2012094598A2/en not_active Ceased
- 2012-01-06 BR BR112013017169A patent/BR112013017169A2/pt not_active IP Right Cessation
- 2012-01-06 JP JP2013548578A patent/JP2014501784A/ja active Pending
- 2012-01-06 EP EP12732499.4A patent/EP2661273A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014501784A5 (enExample) | ||
| Liu et al. | Biomaterials coating for on-demand bacteria delivery: Selective release, adhesion, and detachment | |
| JP6445648B2 (ja) | キレート化複合ミセルを有する薬物キャリア及びその応用 | |
| JP2012067115A5 (enExample) | ||
| JP2008525442A (ja) | 鉄を含む組成物 | |
| JP2013521310A5 (enExample) | ||
| JP2012528890A5 (enExample) | ||
| JP2020514311A5 (enExample) | ||
| JP2010270124A5 (enExample) | ||
| CO6260019A2 (es) | Metodos para el tratamiento de desordenes gastrointestinales independientes de la ingesta de alimento | |
| KR101891357B1 (ko) | 양극성 트랜스 카로티노이드의 경구용 제형 | |
| HRP20191860T1 (hr) | Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka | |
| JP2009530398A5 (enExample) | ||
| HRP20151347T1 (hr) | Nova kombinacija | |
| JP2023011769A5 (enExample) | ||
| JP2019526671A5 (enExample) | ||
| JPS63145229A (ja) | ビタミンｂ６含有医薬組成物 | |
| MX2013005482A (es) | Composicion farmaceutica que contiene sales de citrato y bicarbonato, y su uso para el tratamiento de la cistinuria. | |
| JP2013545802A5 (enExample) | ||
| WO2014200347A1 (en) | Extended release nicotinamide formulation | |
| JP2019504024A5 (enExample) | ||
| Loghman-Adham | Safety of new phosphate binders for chronic renal failure | |
| EP3180036A1 (en) | Metal complexes with bisphosphonate or pyrophosphate useful as imaging agents | |
| JP2019534046A5 (enExample) | ||
| Mohammadian et al. | The advancing of polymeric core–shell ZnO nanocomposites containing 5-fluorouracil for improving anticancer activity in colorectal cancer |